BioNTech SE
22UA
Clasificación en acciones
#1009
BioNTech SE is a biotechnology firm dedicated to the research, development, and... BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
Precio por acción
$92.58
Capitalización bursátil
$23.26B
Cambio (1 día)
-0.06%
Cambio (1 año)
-11.49%
País
DE
Comercio BioNTech SE (22UA)
Categoría
Healthcare
Margen Operativo de BioNTech SE (22UA)
Margen Operativo al October 2026 TTM: -64.63%
Según los informes financieros más recientes y el precio de las acciones de BioNTech SE, el margen operativo actual (TTM) es -64.63%. Al final de 2023, el margen operativo era 18.08%.
Historial de Margen Operativo de BioNTech SE desde 2016 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -64.63% | 35.29% |
| 2024 | -47.77% | -364.21% |
| 2023 | 18.08% | -75.24% |
| 2022 | 73.03% | -9.32% |
| 2021 | 80.54% | -571.27% |
| 2020 | -17.09% | -89.78% |
| 2019 | -167.16% | 296.02% |
| 2018 | -42.21% | -57.57% |
| 2017 | -99.48% | 0.00% |
| 2016 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -100.60% |
US
|
|
| -149.01% | -97.69% |
US
|
|
| 25.57% | -100.40% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.45% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.